Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Common Equity (2020 - 2025)

Historic Common Equity for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $158.1 million.

  • Arcutis Biotherapeutics' Common Equity rose 91.42% to $158.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.1 million, marking a year-over-year increase of 91.42%. This contributed to the annual value of $157.5 million for FY2024, which is 7767.72% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Common Equity stood at $158.1 million for Q3 2025, which was up 91.42% from $139.0 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Common Equity registered a high of $451.0 million during Q1 2021, and its lowest value of $46.7 million during Q3 2023.
  • Moreover, its 5-year median value for Common Equity was $186.4 million (2024), whereas its average is $209.3 million.
  • In the last 5 years, Arcutis Biotherapeutics' Common Equity plummeted by 8274.69% in 2023 and then skyrocketed by 23529.76% in 2024.
  • Arcutis Biotherapeutics' Common Equity (Quarter) stood at $297.7 million in 2021, then decreased by 29.59% to $209.6 million in 2022, then plummeted by 57.69% to $88.7 million in 2023, then surged by 77.68% to $157.5 million in 2024, then increased by 0.34% to $158.1 million in 2025.
  • Its last three reported values are $158.1 million in Q3 2025, $139.0 million for Q2 2025, and $142.7 million during Q1 2025.